Avastin In MBC At Odds With Typical Medicare Coverage Of Off-Label Uses, CMS Official Suggests
This article was originally published in The Pink Sheet Daily
Although CMS’ Jacques declined to speak directly about Medicare coverage plans for Avastin in breast cancer, his comments may shed some light on the direction the agency is leaning.
You may also be interested in...
FDA Commissioner Margaret Hamburg says Genentech has failed to identify a subpopulation of patients in whom the clinical benefits outweigh the risks. The company says it will not appeal the indication’s withdrawal but will pursue a new study in breast cancer.
If not reversed by the Biden Administration, demo program that puts plans at increased risk in catastrophic phase would also enhance negotiating leverage for drugs in the protected classes.
Tactic aims to allow incoming Administration to scrutinize so-called ‘midnight rules’ issued in the final days of the Trump Administration before they take effect. Regulators may also solicit stakeholder comments on delayed rules.